News
Qure (NASDAQ:QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational ...
The United Nations Security Council report pointed out that "some BLA attacks showed a high degree of complexity and brutality", citing Jaffar Express' dramatic hijacking in Pakistan's Balochistan ...
3h
Daily Times on MSNBLA-TTP nexus posing threat to Pakistan's security, says UNSC report
Outlawed terrorist groups - Balochistan Liberation Army (BLA), including its Majeed Brigade, and Tehrik-e Taliban Pakistan (TTP - have "close coordination", according to a United Nations Security ...
The Baloch Army (BLA) has claimed responsibility for an attack on a bus carrying Pakistan Army personnel in the Quetta and Kalak regions of Pakistan. According to the claims, 29 soldiers have been ...
Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...
Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...
Amid the dusty plateaus and strategic choke points of Balochistan, a covert conflict is rapidly intensifying — one that escapes international scrutiny but deeply threatens the region’s stability.
The banned Balochistan Liberation Army (BLA) has intensified its insurgency, emerging as a major terrorist threat in the region. The group was responsible for the recent train hijacking in Bolan ...
The Baloch Liberation Army has claimed responsibility for a bomb blast in Quetta that killed Major Anwar Kakar, a senior ...
Key Takeaways The FDA accepted a Priority Review BLA for RP1 and Opdivo in advanced melanoma, with a PDUFA date of July 22, 2025. The BLA is supported by IGNYTE trial data, focusing on patients with ...
Pakistan, having made unparalleled sacrifices in the global counter-terrorism arena, urged the international community to ...
RICHMOND, Calif., May 06, 2025 -- (BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important derisking events in the pathway to a planned BLA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results